AI Consensus Investment Thesis
Moderna (MRNA) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
PARTIAL SELL
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
SELL ALL$118
-23.6%5-Year
PARTIAL SELL$162
+5.0%Latest flagship insight
Cancer Vaccine Euphoria Meets Stark Manufacturing Realities and Multi-Billion Cash Burn
High consensus confirms that landmark melanoma trial results validate messenger RNA in oncology, but sharp divergence surrounds commercial monetization speed. Persistent operating cash burn, bespoke manufacturing bottlenecks, 50% partnership profit sharing, and elevated discount rates indicate substantial intermediate equity valuation headwinds before sustainable profitability.
This is the latest published deep-analysis batch. Audit published forecasts in full transparency
J.P. Morgan (Titan), Universal Investor (Polymath), Warren Buffett (Value Purist), Machiavelli (Insider), Michael Burry (Vulture), Elon Musk (Visionary), Superintelligence (Anthropologist), Sherlock Holmes (Whistleblower), Ray Dalio (Strategist). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTExecutive Summary
Dotted terms open concise definitions. Browse technical terms
If you invested $10,000 in Moderna at the forecast anchor (2026-09-18): $10,498 in five years versus $13,892 for S&P 500 benchmark.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (USD) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 138.47 | -10.11% | -10.11% | Speculative euphoria cools as autumn vaccination volumes confirm sluggish endemic booster uptake. Markets confront ongoing multi-hundred-million-dollar operating deficits, driving institutional profit-taking and multiple compression under elevated interest rate conditions. |
| Q1 2027 | 126.12 | -8.92% | -18.13% | Full-year financial disclosures confirm multi-billion-dollar net losses and cash burn. High Treasury yields penalize long-duration clinical assets, prompting capital rotation away from pre-profit biopharma toward dependable healthcare earnings. |
| Q2 2027 | 123.48 | -2.09% | -19.84% | Regulatory submission preparations and medical congress abstracts restore speculative interest. Presentation of detailed trial data prompts a tactical relief rally, temporarily counterbalancing structural deficits and ongoing manufacturing buildout expenses. |
| Q3 2027 | 117.69 | -4.69% | -23.60% | Scrutiny of bespoke manufacturing protocols and reimbursement timelines dampens optimism. Off-season respiratory revenue troughs and persistent cost-of-capital pressures resume intermediate valuation multiple compression across institutional portfolios. |
| Q4 2027 | 116.97 | -0.61% | -24.06% | Initial regulatory filing acceptances clarify commercial timelines but reveal steep launch infrastructure outlays. Operating expense reductions take hold, yet cash burn remains elevated, keeping equity multiples anchored to fundamental revenue reality. |
| Q1 2028 | 117.06 | +0.08% | -24.00% | Anticipation of regulatory decisions on personalized oncology therapy drives speculative positioning. Demonstrable operating expense discipline visibly narrows quarterly losses, fostering cautious optimism ahead of critical commercial launch verdicts. |
| Q2 2028 | 120.40 | +2.85% | -21.84% | Regulatory approval of intismeran autogene in adjuvant melanoma triggers institutional accumulation and milestone inflows. Attention swiftly pivots to complex biopsy-to-infusion logistics, limiting runaway speculative expansion to deliverable launch economics. |
| Q3 2028 | 119.08 | -1.10% | -22.70% | Early commercial rollout reveals logistical friction and gradual hospital onboarding. Bespoke patient synthesis costs constrain initial gross margins, tempering euphoric sales projections and triggering mild valuation consolidation. |
| Q4 2028 | 120.62 | +1.30% | -21.69% | Winter respiratory revenue rebounds alongside combination vaccine uptake, while oncology shipments expand. Narrowing operational deficits confirm progress toward cash breakeven, sparking an operational relief rally into year-end. |
| Q1 2029 | 120.18 | -0.37% | -21.98% | Post-winter seasonal revenue moderation and ongoing clinical development expenses induce minor consolidation. Investors focus on unit cost-of-goods trends and payer reimbursement verification across major regional cancer networks. |
| Q2 2029 | 125.73 | +4.62% | -18.38% | Manufacturing yield enhancements and automated synthesis workflows compress patient turnaround times. European regulatory clearances broaden the commercial addressable market, reinforcing institutional confidence in long-term earnings durability. |
| Q3 2029 | 129.46 | +2.97% | -15.95% | Pivotal clinical progress in secondary solid tumor indications expands addressable oncology populations. Commercial revenue steadily absorbs fixed research overhead, supporting modest multiple expansion on verified pipeline diversification. |
| Q4 2029 | 134.78 | +4.11% | -12.50% | Dual-engine revenue contribution from oncology royalties and mature respiratory franchises pushes quarterly operations near cash breakeven. Attaining this operational turnaround milestone eliminates dilutive financing fears, lifting institutional sentiment. |
| Q1 2030 | 137.31 | +1.87% | -10.86% | Normal seasonal post-holiday volume decline prompts slight valuation digestion. Valuation remains supported as the business model successfully transitions from a volatile pandemic play to an established commercial specialty oncology producer. |
| Q2 2030 | 142.61 | +3.86% | -7.42% | Commercial label expansions and international reimbursement agreements drive steady oncology patient volume growth. Expanding manufacturing scale improves gross margins, supporting sustained positive operational cash flow generation. |
| Q3 2030 | 145.63 | +2.12% | -5.46% | Global sovereign biodefense contracts and routine advance purchase orders establish an insulated commercial revenue floor. Positive operational momentum cushions against broader macroeconomic deceleration and competitive pharmaceutical entrants. |
| Q4 2030 | 150.74 | +3.51% | -2.14% | Record commercial product shipments across seasonal combination vaccines and oncology infusions deliver sustained GAAP profitability. Demonstrable operating leverage prompts analysts to raise multi-year terminal cash flow projections. |
| Q1 2031 | 153.05 | +1.53% | -0.64% | Annual financial results confirm full-year operating profitability, completing the corporate turnaround. The equity trades steadily as institutional holders value recurring therapeutic earnings at normalized specialty biopharmaceutical multiples. |
| Q2 2031 | 157.84 | +3.13% | +2.46% | Next-generation pipeline assets in rare diseases and multivalent vaccines advance into late-stage trials organically. Self-funded development without external capital dependency reinforces balance sheet resilience and defensible competitive moats. |
| Q3 2031 | 161.70 | +2.45% | +4.98% | The five-year restructuring window concludes with the business operating as an established, cash-generative biotechnology leader. Valuation multiples find lasting equilibrium, anchored by verifiable cash flows and disciplined capital allocation. |
Moderna presents a classic valuation disconnect where long-term biological validation outruns near-term shareholder economics. The positive Phase 3 INTerpath-001 melanoma data confirms messenger RNA's therapeutic utility beyond prophylactic vaccines. However, trading at 27.4 times trailing revenue with an annual operating deficit exceeding $3.3 billion, the market prices immediate commercial blockbuster economics while disregarding operational realities. Between clinical validation and projected 2028 operational breakeven lies a multi-year scaling transition constrained by bespoke manufacturing turnaround, a 50% profit-sharing commitment with Merck, and ongoing respiratory demand erosion. In a restrictive monetary regimemonetary regimeThe prevailing framework of central-bank policy, interest rates, money creation, and exchange-rate management.View full glossary entry with 5% risk-free hurdle rates, pre-profit biotechnology assets face severe duration penalties.
Key insights
- Bespoke neoantigen synthesis requires patient-specific sequencing, custom formulation, and strict cold-chain logistics, structurally capping gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry far below pandemic-era windfall benchmarks.
- Equal profit sharing with commercialization partner Merck halves attributable oncology cash generation, meaning headline peak product sales translate into modest per-share owner earningsowner earningsAn estimate of cash available to owners after operating costs, taxes, and the capital spending needed to maintain competitive capacity.View full glossary entry.
- Capital preservation via recent zero-coupon convertible issuance extends operating runway into 2028, but converts establish eventual dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry ceilings that limit long-term per-share upside.
Moderna recently proved its messenger RNA technology can successfully treat melanoma skin cancer, sparking a massive rally. However, the business still loses over $3 billion a year as sales for its COVID vaccines decline. Making personalized cancer treatments is slow, expensive, and requires building custom medicine for every individual patient. Because Moderna must also split profits evenly with partner Merck, turning this scientific breakthrough into corporate profits will take years. High interest rates make unprofitable companies risky, suggesting the stock jumped too fast.
Key insights
- Personalized cancer vaccines are custom-made for each patient, preventing high profit marginsprofit marginsProfit margins measure the share of revenue retained as profit after covering specified costs, expressed as a percentage.View full glossary entry typical of mass-produced medicines.
- Moderna splits all cancer vaccine profits 50/50 with partner Merck, reducing direct earnings for shareholders.
- Recent convertible bond financing protects short-term cash reserves, but long-term gains will face future share dilution.
Deep Dive
Prevailing market consensus treats the August 2026 Phase 3 melanoma readout as an unassailable de-risking event that instantly transforms the company into a dominant, high-margin oncology monopoly. Retail buyers and sell-side commentary assume rapid, frictionless regulatory approvals and immediate multi-billion-dollar commercial sales. This optimistic crowd narrative anchors on peak pandemic speed, presuming oncology optionality effortlessly overcomes persistent operating deficits and collapsing respiratory booster demand.
Paywalled preview begins: Deep Dive: detailed analysis
From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Opinions—and what could close the gap?
Market Narrative
What does the market currently expect? Prevailing market consensus treats the August 2026 Phase 3 melanoma readout as an unassailable de-risking event that instantly transforms the company into a dominant, high-margin oncology monopoly. Retail buyers and sell-side commentary assume rapid, frictionless regulatory approvals and immediate multi-billion-dollar commercial sales. This optimistic crowd narrative anchors on peak pandemic speed, presuming oncology optionality effortlessly overcomes persistent operating deficits and collapsing respiratory booster demand.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd materially overestimates near-term cash conversion, creating pronounced share overpricing. The analytical edge lies in recognizing that individualized neoantigen therapy is an operationally complex, craft-scale therapeutic requiring multi-week vein-to-vein turnaround, high unit production costs, and an equal profit split with Merck. Furthermore, discounting deferred cash flows at a 5% benchmark rate reveals that current market capitalizationmarket capitalizationThe market value of an asset or company, commonly calculated for a company as share price multiplied by shares outstanding.View full glossary entry already embeds unproven clinical expansions across multiple solid tumors, leaving equity pricing vulnerable to multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry.
Repricing Catalyst
What could make the market recognize and close that gap? Granular data disclosures and Biologics License Application filing timelines across 2027 will trigger convergence. When medical congress presentations reveal full overall survival hazard ratios and management discloses commercialization capital expenditurescapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry, unit manufacturing costs, and realistic hospital onboarding pacing, expectations will reset. Observable signals will appear when quarterly earnings demonstrate ongoing operational losses despite expense reductions, forcing consensus models to push back self-funded cash breakeven timelines.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Greed
- Volatility
- High Erratic
- Cycle position
- Overshoot
Sentiment exhibits sharp disagreement: momentum participants display extreme greed following positive clinical readouts, whereas fundamental analysts identify an unsustainable speculative overshoot. This positioning tension creates high erratic volatility, requiring multiple quarterly earnings prints to establish fundamental valuation support.
Macro Regime Fit
Does the current market environment support the thesis? The prevailing macroeconomic regimemacroeconomic regimeThe prevailing set of economic conditions including interest rates and inflation that influence asset pricing.View full glossary entry delivers a direct headwind. Benchmark policy rates near 4.00% and ten-year Treasury yields touching 5.0% establish punitive discount rates for long-duration biotechnology assets with negative free cash flownegative free cash flowA condition where cash outflows for operations and investment exceed cash generated in the period.View full glossary entry. Higher hurdle rates compress speculative valuation multiples and raise capital costs, punishing cash-burning enterprises regardless of clinical pipeline promise.
Advisor Disagreement
What do our AI Advisors disagree about most? The decisive disagreement centers on the commercial margin structure and cash breakeven velocity of individualized oncology. Optimistic perspectives assume that positive Phase 3 data guarantees rapid regulatory approval, swift automated manufacturing scaling, and operating profitability by 2028. Conversely, conservative forensic views argue that patient-specific neoantigen synthesis imposes rigid cost floors, extended vein-to-vein turnaround times, and equal profit sharing with Merck that defer meaningful free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry into the 2030s. The debate will resolve as management discloses detailed manufacturing cost-of-goods and granular INTerpath-001 overall survival hazard ratios during 2027 regulatory filings.
Base-Case Forces
Event Risk ScoreVery High88/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Individualized neoantigen oncology clinical validation | Innovation And Product | +32% | +52% | Phase 3 INTerpath-001 trial data demonstrates statistically significant recurrence-free and distant metastasis-free survival in resected melanoma. Partnered with Merck, this breakthrough validates messenger RNA therapeutic efficacy outside infectious disease, unlocking multi-billion-dollar oncology market potential. Clinical validation anchors franchise terminal valueterminal valueThe present value of all future cash flows beyond the explicit forecast period.View full glossary entry and diversifies revenue streams away from seasonal respiratory portfolios over the forecast horizon. |
| Merck global oncology commercial partnership | Competitive Positioning | +22% | +36% | The worldwide collaboration with Merck provides indispensable commercial infrastructure, shared clinical development costs, and immediate hospital distribution access alongside Keytruda. Merck's established oncology salesforce eliminates billions in standalone commercialization buildout outlays. This alliance substantially de-risks execution, accelerates clinical adoption across major cancer centers, and secures high-margin commercial milestone cash inflows through 2031. |
| Aggressive research and operating expense rationalization | Operational Efficiency | +17% | +33% | Executive cost-restructuring initiatives have trimmed annual research expenditures from $4.84 billion toward targeted ranges below $3.5 billion by 2027. Terminating non-core exploratory pipelines, streamlining headcount, and focusing capital exclusively on registrational programs stems catastrophic balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry attrition. This operational discipline visibly narrows quarterly operating deficits and establishes a credible glidepath toward cash breakeven. |
| Multi-product respiratory commercial portfolio expansion | Competitive Positioning | +14% | +24% | Regulatory clearance of mFLUSIVA and advancement of combination COVID-flu candidates establish a recurring non-monovalent respiratory base. Bundled seasonal immunizations provide convenient clinical administration across aging demographics. While respiratory markets remain competitive, recurring public health tenders provide an essential non-dilutive revenue baseline, absorbing manufacturing overhead and supporting ongoing clinical oncology research through commercialization. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Excessive valuation multiplevaluation multipleA ratio comparing market or enterprise value with a financial measure such as earnings, revenue, book value, or cash flow.View full glossary entry speculative overshoot | Capital Allocation | -34% | -12% | Trading at 27.4 times trailing twelve-month revenue while generating multi-billion-dollar operating deficits represents severe market overshoot. The price reflects immediate commercial blockbuster realization, ignoring regulatory lead times and initial commercialization lag. As momentum flows dissipate, multiples must compress toward normalized biotechnology peer averages, exerting substantial intermediate valuation drag. |
| Bespoke personalized manufacturing cost friction | Operational Efficiency | -24% | -34% | Individualized neoantigen therapy relies on patient-specific biopsy sequencing, bespoke synthesis, and complex cold-chain logistics within a tight six-week turnaround. This personalized paradigm generates elevated unit cost of goods soldcost of goods soldCost of goods sold (COGS) represents the direct costs of producing or delivering the goods sold by a business.View full glossary entry, capping gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry far below conventional vaccines. Coupled with Merck's 50% profit split, net cash conversion will lag aggressive sell-side expectations. |
| Structural respiratory vaccine demand erosion | Sector And Industry | -20% | -28% | Widespread public immunization fatigue, diminished mandates, and formidable competition from pharmaceutical incumbents enforce a low ceiling on commercial respiratory revenue. Subdued consumer uptake across monovalent boosters and lagging market share in RSV products compress top-line volume, stranding high-cost manufacturing capacity and depressing return on invested capitalreturn on invested capitalReturn on invested capital (ROIC) measures how efficiently a business generates after-tax operating profit from the capital invested in its operations.View full glossary entry across the forecast horizon. |
| Restrictive monetary policy and discount penalties | Macroeconomic And Macrofinancial | -17% | -10% | Policy interest rates near 4.00% and ten-year benchmark Treasury yields hovering around 5.0% establish a punishing discount ratediscount rateThe rate used to convert future cash flows or values into present value.View full glossary entry for long-duration biotech assets. Elevated capital costs heavily penalize cash-burning enterprises whose primary earnings inflection is deferred past 2028. Restrictive monetary conditions restrict speculative risk tolerance, compressing long-term discounted cash flow valuations. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Intismeran overall survival statistical failure | 32% | -50% | Mature overall survival disclosures from the INTerpath-001 melanoma study in 2027 could fail to demonstrate statistically significant lifespans separation despite initial recurrence-free gains. Regulators would impose restrictive label indications and payers would resist premium reimbursement pricing. This clinical shortfall would annihilate the primary growth pillar supporting the company's valuation, triggering catastrophic institutional derating. Strong Phase 2 survival hazard ratios keep trial failure probability below fifty percent. |
| Adverse federal vaccine schedule restriction | 26% | -38% | Federal health overseers could alter immunization schedules by early 2027, removing messenger RNA COVID-19 or combination formulations from routine public recommendation guidelines. Such regulatory action would sever automatic insurance reimbursement mandates and severely crush domestic seasonal demand. Resulting top-line destruction would widen quarterly cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry, rapidly depleting balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry liquidity and forcing distressed financing. Ongoing litigation and commercial appeal keep this disruptive political event below fifty percent. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Accelerated multi-tumor oncology clinical victory | 32% | +58% | Phase 3 INTerpath-002 trials in resected non-small cell lung cancer could report statistically significant disease-free survival benefits ahead of schedule by late 2028. Unlocking large-market lung cancer indications expands the addressable patient population fivefold, prompting immediate regulatory priority reviews and triggering over $1.5 billion in commercial milestone payments from Merck. Biological heterogeneity and complex tumor microenvironments keep realization probability strictly below fifty percent. |
| Automated microfluidic synthesis cost breakthrough | 24% | +42% | Engineering breakthroughs in automated desktop microfluidics and synthetic molecular biology could slash individualized therapy turnaround times from six weeks to ten days by 2029. Reducing bespoke production costs by 70% transforms personalized therapeutics from an artisanal hospital procedure into a scalable, high-margin commercial reality, expanding operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry by over 1,500 basis points. Rigorous good manufacturing compliance requirements keep probability in the tail range. |
Company Financial Analysis
Moderna Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
AI Review
Moderna's income statement reflects the severe reality of a post-pandemic financial transition. Following historic peaks, fiscal 2025 revenue fell 39.2% to $1.94 billion, producing a net loss of $2.82 billion. Through the second quarter of 2026, trailing twelve-month revenue stabilized near $2.23 billion, but operating losses remained staggering at $3.32 billion. This persistent deficit demonstrates that headline commercial approvals cannot instantly replace lost pandemic revenues. While management has trimmed research spending to slow the cash bleed, commercial receipts from seasonal vaccines remain insufficient to cover ongoing late-stage clinical trials. Until cancer therapies reach the market, the enterprise remains heavily reliant on pre-existing liquidity reserves to fund operations.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 1.9B | USD -2.8B | USD -2.1B |
| 2024 | USD 3.2B | USD -3.6B | USD -4.1B |
| 2023 | USD 6.8B | USD -4.7B | USD -3.8B |
| 2022 | USD 18.9B | USD 8.4B | USD 4.6B |
| 2021 | USD 17.7B | USD 12.2B | USD 13.3B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | -- | TTM | Loss-making | USD / USD |
| 2024 | -- | TTM | Loss-making | USD / USD |
| 2023 | -- | TTM | Loss-making | USD / USD |
| 2022 | 8.7x | Annual | Native | USD / USD |
| 2021 | 9.0x | Annual | Native | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
AI Review
Profitability metrics illustrate extreme negative operating leverage following the loss of pandemic scale. Gross margin stabilized near 55.3% in fiscal 2025 as inventory write-offs ceased, yet operating margins remained deeply underwater at negative 158%. Fixed research and clinical infrastructure costs heavily outweigh reduced commercial vaccine receipts. This margin gap proves that manufacturing economics differ drastically between mass vaccines and customized therapeutics. Personalized cancer treatments require individual tumor sequencing and custom synthesis, creating substantial unit costs. Operating margins cannot sustainably inflect until high-margin oncology products reach commercial scale and absorb fixed corporate overhead.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD -3.1B | -158.1% | -145.2% |
| 2024 | USD -3.9B | -123.3% | -111.3% |
| 2023 | USD -4.2B | -61.9% | -68.8% |
| 2022 | USD 9.4B | 49.9% | 44.3% |
| 2021 | USD 13.3B | 75.0% | 68.8% |
Balance sheet and leverage
AI Review
Moderna's balance sheet retains optical short-term liquidity while enduring steady underlying erosion. Stockholders' equity contracted from $19.12 billion in 2022 to $8.65 billion in 2025 under persistent operating deficits. Total cash and investments stood near $6.9 billion in mid-2026 before being augmented by a $2.6 billion zero-coupon convertible notes offering. While this financing extends the cash runway into 2028 without immediate dilution, it introduces long-term obligations alongside an existing $1.5 billion credit facility. Headline cash provides short-term safety, but persistent cash burn leaves the company vulnerable if commercial milestones encounter regulatory delays or clinical setbacks.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 1.9B | USD 5.8B | USD 679M net cash | 3.29x |
| 2024 | USD 747M | USD 7B | USD 1.2B net cash | 3.67x |
| 2023 | USD 1.2B | USD 8.6B | USD 1.7B net cash | 3.42x |
| 2022 | USD 1.2B | USD 9.9B | USD 2B net cash | 2.73x |
| 2021 | USD 916M | USD 10.7B | USD 5.9B net cash | 1.76x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
AI Review
Management has shifted from aggressive post-pandemic facility expansion toward strict capital rationing. Capital expenditures dropped from 32.9% of revenue in 2024 to 9.88% in 2025 as major manufacturing facilities were completed. Annual research and development spending fell 31.1% in 2025 to $3.13 billion as non-core exploratory pipelines were discontinued. This disciplined spending pivot preserves vital cash reserves while concentrating investment on pivotal Phase 3 programs. However, tailoring treatments for individual cancer patients will eventually demand specialized automation. While current restraint protects near-term solvency, underinvesting in high-throughput manufacturing could create future bottlenecks when personalized cancer therapies enter broad commercial distribution.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 192M | USD 3.1B |
| 2024 | USD 1.1B | USD 4.5B |
| 2023 | USD 707M | USD 4.8B |
| 2022 | USD 400M | USD 3.3B |
| 2021 | USD 284M | USD 2B |
Quarterly Forecast Scenarios
Moderna Averaged Consensus Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Quarter | Bear case (USD) | Base case (USD) | Bull case (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $135.56 | $138.42 | $144.80 | $750.26 | |
| $122.00 | $125.98 | $137.56 | $736.44 | |
| $104.92 | $122.48 | $137.99 | $743.40 | |
| $93.38 | $116.91 | $132.85 | $755.15 | |
| $79.37 | $116.72 | $143.17 | $776.22 | |
| $69.85 | $115.76 | $150.32 | $787.13 | |
| $75.43 | $119.31 | $162.35 | $802.83 | |
| $63.37 | $119.71 | $173.71 | $812.05 | |
| $51.96 | $122.42 | $192.82 | $839.18 | |
| $47.80 | $123.36 | $198.61 | $850.50 | |
| $49.71 | $129.99 | $216.48 | $872.39 | |
| $52.20 | $134.79 | $229.47 | $885.51 | |
| $55.33 | $140.91 | $247.83 | $909.56 | |
| $59.21 | $143.40 | $257.74 | $916.13 | |
| $61.57 | $150.76 | $283.52 | $936.51 | |
| $63.42 | $154.57 | $297.69 | $947.34 | |
| $64.69 | $160.68 | $318.53 | $969.59 | |
| $65.34 | $163.92 | $328.09 | $979.99 | |
| $67.30 | $169.88 | $347.77 | $999.60 | |
| $68.64 | $174.84 | $361.68 | $1,012 |
Behind the synthesis
How each opinion shapes the consensus
The synthesized consensus is anchored by a compelling, independently supported empirical pattern: while positive Phase 3 INTerpath-001 melanoma data validates messenger RNA outside infectious disease, the market's parabolic re-rating to 27.4 times sales severely disconnects from underlying commercial economics. Correlated assumptions across optimistic submissions mistakenly treat clinical validation as immediate commercial cash generation, overlooking bespoke manufacturing logistics, multi-week turnaround times, and equal partnership profit sharing. Conversely, the strongest credible contrarian insight confirms that recent non-dilutive zero-coupon convertible financing eliminates imminent solvency distress, extending runway toward 2028 commercialization. Relative weights heavily reward submissions grounded in primary SEC filings, audited balance sheets, and realistic unit cost-of-goods calculations, while downweighting models that assume either catastrophic liquidity collapse or frictionless, software-like margin expansion. Material unresolved uncertainty persists regarding overall survival durability in oncology and regulatory stability across domestic vaccine schedules, dictating a path characterized by near-term multiple compression followed by measured, execution-driven recovery.
Universal Investor AI
The Polymath
Opus 5Outstanding forensic analysis incorporating recent zero-coupon convertible note mechanics, capped calls, and precise dilution thresholds. It correctly reconciles commercial partnership economics with elevated discount rates, establishing an exceptionally sound risk-adjusted baseline path.
Universal Investor AI
The Polymath
GPT-6 AstraExemplary primary source grounding in SEC filings, Form 10-Q disclosures, and shared partnership terms. It rigorously differentiates headline clinical efficacy from per-share distributable cash flow, offering the most causally consistent path among all submissions.
Universal Investor AI
The Polymath
Gemini 3.8 FlashThoroughly articulates the temporal lag between headline clinical readouts and commercial cash realization. Its balanced appraisal of combination respiratory portfolio defense versus bespoke production margin compression provides robust, evidence-backed forecasting value.
Michael Burry AI
The Vulture
Gemini 3.8 FlashStrong forensic identification of bespoke manufacturing cost structures, 50% partnership profit splits, and credit facility covenants. It anchors grounded skepticism regarding personalized therapy margins, though its severe near-term debt distress scenario is slightly overstated post-convertible issuance.
J.P. Morgan AI
The Titan
Gemini 3.8 FlashDelivers rigorous scrutiny of commercial distribution barriers in seasonal influenza against established pharmaceutical incumbents. While its long-term operating margin normalization is slightly optimistic, its near-term multiple compression thesis is well supported by commercial realities.
Niccolo Machiavelli AI
The Insider
Gemini 3.8 FlashOffers valuable geopolitical and institutional analysis regarding international sovereign biosecurity procurement and domestic regulatory friction. Its bull-case recovery relies heavily on smooth commercial oncology execution, somewhat underestimating initial turnaround bottlenecks across cancer centers.
Ray Dalio AI
The Strategist
Gemini 3.8 FlashDemonstrates sound macro awareness regarding elevated hurdle rates and discount penalties on long-duration assets. However, its terminal path projects an aggressive valuation recovery that minimizes prolonged competitive pressures across respiratory markets and bespoke production hurdles.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashProvides a balanced view of platform modularity alongside realistic appraisal of six-week vein-to-vein turnaround logistics. The long-term return trajectory slightly overstates margin expansion velocity across non-melanoma indications, necessitating a calibrated moderate weight.
Elon Musk AI
The Visionary
Gemini 3.8 FlashPresents an astute contrast between frictionless digital software scaling and physical manufacturing bottlenecks in bespoke neoantigen synthesis. Its later-stage path relies on rapid technological breakthroughs in automated microfluidics that remain unproven, limiting its weight.
Sherlock Holmes AI
The Whistleblower
Gemini 3.8 FlashProvides incisive forensic examination of clinical trial effect reporting, noting the absence of mature overall survival hazard ratios in initial press disclosures. It appropriately models post-euphoria multiple contraction, though its outer-year recovery is somewhat abrupt.
Universal Investor AI
The Polymath
Gemini 3.8 FlashCorrectly identifies multiple mean-reversion risks and balance sheet equity erosion under sustained research expenditure. It somewhat overstates the probability of dilutive equity financing by overlooking the cash runway afforded by recent convertible debt issuance.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashSolid owner-earnings discipline emphasizing negative cash conversion, idle manufacturing charges, and restrictive debt covenants. However, it takes an overly conservative view of pipeline optionality across latent virus and respiratory combinations, limiting its weight.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashThis report correctly highlights acute owner earnings deficits, ongoing book value depletion, and extreme sales multiple disconnects. However, its excessively punitive liquidation framing underweights validated neoantigen trial success and non-dilutive government partnerships, warranting a modest weighting.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashProvides a useful thermodynamic critique of fixed cost structures against crashing endemic vaccine volumes. Nonetheless, it heavily discounts late-stage clinical oncology derisking and assumes extreme competitive displacement, justifying a minimal relative allocation.
Research Provenance
References & Context
This Moderna consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher webShowing the top 15 of 141 deduplicated sources retained for this batch.
- 01MFLUSIVA | FDAfda.gov
- 022026 Moderna NPSsec.gov
- 038-Ksec.gov
- 04Form 8-Ksec.gov
- 05Moderna, Inc. - Form 8-K - FY2026sec.gov
- 06mrna-20251231sec.gov
- 07www.sec.govsec.gov
- 08Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma - Merck.commerck.com
- 09Cancer vaccine win restores Wall Street’s faith in Moderna | BioPharma Divebiopharmadive.com
- 10Merck and Moderna's Intismeran Autogene Plus Pembrolizumab Meets Endpoints in Phase 3 Melanoma Trial | BioPharm Internationalbiopharminternational.com
- 11Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future - BioSpacebiospace.com
- 12The State of US Vaccine Policy — Feb 19, 2026 | CIDRAPcidrap.umn.edu
- 13The State of US Vaccine Policy — May 28, 2026 | CIDRAPcidrap.umn.edu
- 14ACIP: HHS rewrites rules governing key CDC vaccine committee | CNNcnn.com
- 15CDC vaccine committee drops push to stop recommending mRNA Covid-19 shots, for now | CNNcnn.com
And 126 more sources were used and retained in the batch inventory.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.